



ASX ANNOUNCEMENT

12 March 2025

Lodgement of Cleansing Prospectus

12 March 2025 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) is pleased to announce that it has lodged a cleansing prospectus (**Prospectus**) with ASIC and ASX for the offer and issue of convertible notes, options and placement shares, following the ‘Second Special Purchase’ drawdown of the convertible securities ‘Facility’ as previously described in the Company’s announcement of 28 February 2025.

The indicative timetable in the prospectus is as follows:

Event	Date
Lodgement of Prospectus with ASIC and ASX	12 March 2025
Open Date	19 March 2025
Closing Date	20 March 2025

The primary purpose of this Prospectus is to remove any on-sale restrictions in relation to the Shares referenced in the proposed issue of securities (Appendix 3B) as lodged with the ASX today.

Authorised for release by the Board of Directors, Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology. **Learn more at:** www.canngrouponlimited.com | www.satipharm.com